GIP and obesity disorder: The emergence of glucagon‐like‐peptide‐1 receptor agonists (GLP‐1RAs) and dual glucose‐dependent insulinotropic polypeptide (GIP)/GLP‐1 receptor agonists has fundamentally transformed obesity management, offering highly efficacious pharmacological approaches to weight loss.